These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35715470)

  • 1. Clinical value of urinary cytokines/chemokines as prognostic markers in patients with crescentic glomerulonephritis.
    Jeon J; Park J; Boo HJ; Yang KE; Lee CJ; Lee JE; Kim K; Kwon GY; Huh W; Kim DJ; Kim YG; Jang HR
    Sci Rep; 2022 Jun; 12(1):10221. PubMed ID: 35715470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic analysis of crescentic glomerulonephritis with acute kidney injury: a single-center cohort with 5-year follow-up.
    Chen Z; Xu J; Wu J; Xue C; Ruan M; Mei C; Mao Z
    Int Urol Nephrol; 2022 Sep; 54(9):2375-2383. PubMed ID: 35157218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis.
    Tam FW; Sanders JS; George A; Hammad T; Miller C; Dougan T; Cook HT; Kallenberg CG; Gaskin G; Levy JB; Pusey CD
    Nephrol Dial Transplant; 2004 Nov; 19(11):2761-8. PubMed ID: 15353578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urine Epidermal Growth Factor, Monocyte Chemoattractant Protein-1 or Their Ratio as Biomarkers for Interstitial Fibrosis and Tubular Atrophy in Primary Glomerulonephritis.
    Worawichawong S; Worawichawong S; Radinahamed P; Muntham D; Sathirapongsasuti N; Nongnuch A; Assanatham M; Kitiyakara C
    Kidney Blood Press Res; 2016; 41(6):997-1007. PubMed ID: 27988512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary chemokine C-X-C motif ligand 16 and endostatin as predictors of tubulointerstitial fibrosis in patients with advanced diabetic kidney disease.
    Lee YH; Kim KP; Park SH; Kim DJ; Kim YG; Moon JY; Jung SW; Kim JS; Jeong KH; Lee SY; Yang DH; Lim SJ; Woo JT; Rhee SY; Chon S; Choi HY; Park HC; Jo YI; Yi JH; Han SW; Lee SH
    Nephrol Dial Transplant; 2021 Jan; 36(2):295-305. PubMed ID: 31598726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloperoxidase-antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis with rheumatoid arthritis: a comparison of patients without rheumatoid arthritis.
    Kurita N; Mise N; Fujii A; Mori M; Sai K; Nishi T; Suzuki T; Tagawa H; Sugimoto T
    Clin Exp Nephrol; 2010 Aug; 14(4):325-32. PubMed ID: 20339893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early postoperative urinary MCP-1 as a potential biomarker predicting acute rejection in living donor kidney transplantation: a prospective cohort study.
    Jang HR; Kim M; Hong S; Lee K; Park MY; Yang KE; Lee CJ; Jeon J; Lee KW; Lee JE; Park JB; Kim K; Kwon GY; Kim YG; Kim DJ; Huh W
    Sci Rep; 2021 Sep; 11(1):18832. PubMed ID: 34552150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary fractalkine and monocyte chemoattractant protein-1 as possible predictors of disease activity of childhood glomerulonephritis.
    Aizawa T; Imaizumi T; Tsuruga K; Watanabe S; Yoshida H; Kumagai N; Ito E; Tanaka H
    Tohoku J Exp Med; 2013 Dec; 231(4):265-70. PubMed ID: 24284376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel histopathologic predictors for renal outcomes in crescentic glomerulonephritis.
    Lim JH; Han MH; Kim YJ; Jeon Y; Jung HY; Choi JY; Cho JH; Kim CD; Kim YL; Lee H; Kim DK; Moon KC; Park SH
    PLoS One; 2020; 15(7):e0236051. PubMed ID: 32716952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T helper (Th)-cytokines in the urine of patients with primary glomerulonephritis treated with immunosuppressive drugs: Can they predict outcome?
    Kalavrizioti D; Gerolymos M; Rodi M; Kalliakmani P; Provatopoulou S; Eleftheriadis T; Mouzaki A; Goumenos DS
    Cytokine; 2015 Dec; 76(2):260-269. PubMed ID: 26307557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of a Histologic Scoring Index for C3 Glomerulopathy.
    Caravaca-Fontán F; Trujillo H; Alonso M; Díaz-Encarnación M; Cabello V; Ariceta G; Quintana LF; Marco H; Barros X; Ramos N; Rodríguez-Mendiola N; Cruz S; Fernández-Juárez G; Rodríguez E; de la Cerda F; Pérez de José A; López I; Fernández L; Pérez Gómez V; Ávila A; Bravo L; Lumbreras J; Allende N; Sanchez de la Nieta MD; Olea T; Melgosa M; Huerta A; Miquel R; Mon C; Fraga G; de Lorenzo A; Draibe J; González F; Shabaka A; Illescas ML; Calvo C; Oviedo V; Da Silva I; Goicoechea de Jorge E; Caravaca F; Praga M;
    Am J Kidney Dis; 2021 May; 77(5):684-695.e1. PubMed ID: 33359150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor renal outcomes in patients with anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis and normal renal function at diagnosis.
    Hanaoka H; Ota Y; Takeuchi T; Kuwana M
    Clin Rheumatol; 2016 Feb; 35(2):495-500. PubMed ID: 26742758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urine epidermal growth factor, monocyte chemoattractant protein-1 or their ratio as predictors of complete remission in primary glomerulonephritis.
    Chanrat E; Worawichawong S; Radinahamed P; Sathirapongsasuti N; Nongnuch A; Assanatham M; Udomsubpayakul U; Kitiyakara C
    Cytokine; 2018 Apr; 104():1-7. PubMed ID: 29414320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of CX3CL1/fractalkine by mesangial cells in vitro and in acute anti-Thy1 glomerulonephritis in rats.
    Chen YM; Hu-Tsai MI; Lin SL; Tsai TJ; Hsieh BS
    Nephrol Dial Transplant; 2003 Dec; 18(12):2505-14. PubMed ID: 14605272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Clinicopathologic Spectrum of Rapidly Progressive Glomerulonephritis Based on Glomerular Immune Deposition and Antineutrophil Cytoplasmic Antibody.
    Han F; Chen L; Le J; Choong P; Xu Y; Wang H; Chen J
    Appl Immunohistochem Mol Morphol; 2015; 23(10):704-10. PubMed ID: 26551339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of fractalkine in human crescentic glomerulonephritis.
    Furuichi K; Wada T; Iwata Y; Sakai N; Yoshimoto K; Shimizu M; Kobayashi K; Takasawa K; Kida H; Takeda S; Matsushima K; Yokoyama H
    Nephron; 2001 Apr; 87(4):314-20. PubMed ID: 11287774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological features and prognostic analysis of 49 cases with crescentic glomerulonephritis.
    Wu T; Peng J; Meng T; Liu Q; Ao X; Lin W; Yin H; Chen J; Pu J; Peng Z; Peng W; Li X; Xiao X; Zhou Q; Zhong Y; Xiao P
    Exp Ther Med; 2019 Nov; 18(5):3984-3990. PubMed ID: 31611938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Changes of urinary monocyte chemotactic protein 1 and epidermal growth factor and their correlations with clinicopathology in idiopathic membranous nephropathy patients].
    Zheng S; Zhao ZH; Liu ZJ; Wang DH; Liu DW; Liu ZS
    Zhonghua Yi Xue Za Zhi; 2020 Apr; 100(16):1230-1234. PubMed ID: 32344494
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors.
    Tanna A; Guarino L; Tam FW; Rodriquez-Cubillo B; Levy JB; Cairns TD; Griffith M; Tarzi RM; Caplin B; Salama AD; Cook T; Pusey CD
    Nephrol Dial Transplant; 2015 Jul; 30(7):1185-92. PubMed ID: 25016608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes in patients with biopsy-proved diabetic nephropathy compared to isolated lupus or crescentic glomerulonephritis.
    Chou YH; Lin WC; Chen YM
    Diabetes Res Clin Pract; 2019 Feb; 148():144-151. PubMed ID: 30641169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.